Literature DB >> 12638394

Effect of high-fat breakfast and moderate-fat evening meal on the pharmacokinetics of vardenafil, an oral phosphodiesterase-5 inhibitor for the treatment of erectile dysfunction.

Prabhu Rajagopalan1, Arthur Mazzu, Chenghua Xia, Ray Dawkins, Pavur Sundaresan.   

Abstract

The effects of food on the pharmacokinetics of vardenafil were examined in 25 healthy adult males. Single-dose vardenafil 20 mg was administered in a randomized four-way crossover design after an overnight fast (at 8 a.m.), after consumption of a high-fat breakfast (at 8 a.m.), on an empty stomach (at 6 p.m.), and after a typical moderate-fat evening meal (at 6 p.m.). Serial blood samples were analyzed for vardenafil and metabolite (M1) levels. When administered after an overnight fast and after a high-fat breakfast, vardenafil geometric mean Cmax was 17.14 and 14.0 micrograms/L, respectively, and AUC was 66.78 and 67.09 micrograms./h/L, respectively; the median tmax was 1 hour under fasting conditions and 2 hours with consumption of high-fat breakfast. When administered in the evening on an empty stomach and after a moderate-fat meal, vardenafil geometric mean Cmax was 14.22 and 13.04 micrograms/L, respectively, and AUC was 51.97 and 59.12 micrograms.h/L, respectively. The median tmax was 1 hour after fasting or a moderate-fat meal in the evening. All treatments were well tolerated. Thus, while a high-fat meal may alter Cmax slightly and delay the absorption up to 1 hour, a moderate-fat meal has no clinically relevant effect on vardenafil pharmacokinetics. Dosage changes are not warranted based on the wide therapeutic index and the efficacy observed with vardenafil in Phase III studies that were not restricted with respect to food.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12638394     DOI: 10.1177/0091270002250604

Source DB:  PubMed          Journal:  J Clin Pharmacol        ISSN: 0091-2700            Impact factor:   3.126


  17 in total

1.  Pharmacokinetics of a new orodispersible tablet formulation of vardenafil: results of three clinical trials.

Authors:  Roland Heinig; Boris Weimann; Hartmut Dietrich; Michael-Friedrich Böttcher
Journal:  Clin Drug Investig       Date:  2011       Impact factor: 2.859

2.  High inter-individual variability of vardenafil pharmacokinetics in patients with pulmonary hypertension.

Authors:  A M Sandqvist; D Henrohn; J Schneede; M Hedeland; H C Egeröd; U G Bondesson; B G Wikström
Journal:  Eur J Clin Pharmacol       Date:  2012-06-26       Impact factor: 2.953

Review 3.  Clinical update on phosphodiesterase type-5 inhibitors for erectile dysfunction.

Authors:  Alberto Briganti; Andrea Salonia; Federico Deho'; Giuseppe Zanni; Luigi Barbieri; Patrizio Rigatti; Francesco Montorsi
Journal:  World J Urol       Date:  2005-11-05       Impact factor: 4.226

4.  PDE-5 Inhibitor Therapy for Erectile Dysfunction Secondary to Nerve-Sparing Radical Retropubic Prostatectomy.

Authors:  Harin Padma-Nathan
Journal:  Rev Urol       Date:  2005

Review 5.  The use of phosphodiesterase 5 inhibitors with concomitant medications.

Authors:  G Corona; E Razzoli; G Forti; M Maggi
Journal:  J Endocrinol Invest       Date:  2008-09       Impact factor: 4.256

Review 6.  Vardenafil: a review of its use in erectile dysfunction.

Authors:  Gillian M Keating; Lesley J Scott
Journal:  Drugs       Date:  2003       Impact factor: 9.546

Review 7.  Spotlight on vardenafil in erectile dysfunction.

Authors:  Gillian M Keating; Lesley J Scott
Journal:  Drugs Aging       Date:  2004       Impact factor: 3.923

8.  Intranasal microemulsion of sildenafil citrate: in vitro evaluation and in vivo pharmacokinetic study in rabbits.

Authors:  Ahmed H Elshafeey; Ehab R Bendas; Osama H Mohamed
Journal:  AAPS PharmSciTech       Date:  2009-03-31       Impact factor: 3.246

Review 9.  Vardenafil for the treatment of erectile dysfunction: an overview of the clinical evidence.

Authors:  Antonio Martín Morales; Vincenzo Mirone; John Dean; Pierre Costa
Journal:  Clin Interv Aging       Date:  2009-12-29       Impact factor: 4.458

Review 10.  Toward a new 'EPOCH': optimising treatment outcomes with phosphodiesterase type 5 inhibitors for erectile dysfunction.

Authors:  R Sadovsky; G B Brock; S W Gutkin; S Sorsaburu
Journal:  Int J Clin Pract       Date:  2009-08       Impact factor: 2.503

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.